The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.
Andrea Cercek
Research Funding - Lorus; Synta
Cara Siegel
No relevant relationships to disclose
Diane Lauren Reidy
Consultant or Advisory Role - Novartis; Pfizer
Research Funding - ImClone Systems; Merck
Leonard Saltz
Consultant or Advisory Role - Alchemia; Biothera; Delcath Systems ; ImClone Systems; Merck; Novartis; Roche
Research Funding - Amgen; Biothera; Bristol-Myers Squibb; CureTech; Genentech; ImClone Systems; Lilly; Merck; Pfizer; Roche